A small implant placed in the eye gradually releases medication. A capsule containing living cells acts inside the body as a microscopic therapeutic protein production unit. A single injection protects against HIV for six months. Another treatment attempts to replace daily insulin injections with a weekly dose. In the arm, a thin contraceptive implant can now remain effective for five years. Medical treatment is changing its form, and with it, the patient’s relationship with medicine is shifting.
A search through official announcements, approvals, and evaluations by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) fully captures these shifts in managing various conditions and states that were treated with pills and injections for decades. Dozens of innovative ideas from nearly all global manufacturing companies are currently in the study stage, signaling that the coming years will be particularly significant for medicine worldwide.
Six Months of Treatment from a Single Refill
In July 2026, the EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for Susvimo, a treatment for wet age-related macular degeneration, a severe condition that can cause central vision loss. Instead of the usual repeated injections into the eye, a small, refillable implant is surgically placed to gradually release ranibizumab.
The implant is refilled every 24 weeks. According to the EMA, phase 3 study results regarding vision preservation were comparable to those of injections administered every four weeks. For an elderly patient, the difference between a monthly intervention and one every six months is not a minor detail; it means fewer appointments, less travel, reduced reliance on relatives, and lower psychological stress. However, the treatment carries costs and risks, requiring surgical placement, specialized refilling, and systematic monitoring. Furthermore, the CHMP positive opinion represents a major, yet final step before full European authorization.
Living Cells and Biannual HIV Prophylaxis
Even more striking is a therapy approved by the FDA in March 2025. Encelto is intended for adults with type 2 idiopathic macular telangiectasia, a rare degenerative retinal disease. The implant contains encapsulated allogeneic cells modified to produce a therapeutic protein, which the FDA classifies as a cellular gene therapy. In simple terms, a small biological production unit is implanted into the eye, producing the substance continuously where it is needed.
Meanwhile, lenacapavir (marketed in Europe as Yeytuo) received EU marketing authorization in August 2025 for pre-exposure prophylaxis (PrEP) against HIV. Following initial doses, it is administered via subcutaneous injection every six months. In a primary study, zero new infections were recorded among 2,134 individuals receiving the treatment, while a second study recorded two infections among 2,179 participants. Officials emphasize that convenience must not replace responsibility, as pre-administration HIV testing is mandatory and the drug remains active in the body for an extended period.
Weekly Insulin and Five-Year Contraception
In June 2026, the EMA committee issued a positive opinion for Onswik, a baseline insulin administered once a week to adults with type 2 diabetes. In QWINT 1-4 studies, weekly insulin achieved reductions in glycated hemoglobin comparable to daily baseline insulin, dropping administration from roughly 365 injections a year to 52.
In contraception, the FDA extended the approved duration of Nexplanon to five years in January 2026. The thin implant placed under the arm’s skin continuously releases a small amount of etonogestrel. While it frees women from daily pill-taking, autonomy remains tied to healthcare access for removal.
Medical Caution and Future Outlook
Long-acting therapies promise fewer doses, fewer doctor visits, better compliance, and greater freedom for patients. However, implants often carry higher costs than standard injections. As these technologies rapidly develop, the current healthcare landscape could shift drastically within the decade, making proper medical consultation and personalized evaluation essential for every patient.




